MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Eli Lilly and Company Depreciation & Amortization 2011-2026 | LLY
Annual Depreciation & Amortization Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 B | 1.77 B | 1.53 B | 1.52 B | 1.55 B | 1.32 B | 1.23 B | 1.61 B | 1.57 B | 1.5 B | 1.43 B | 1.38 B | 1.45 B | 1.46 B | 1.37 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2 B | 1.23 B | 1.51 B |
Quarterly Depreciation & Amortization Eli Lilly and Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 463 M | - | - | 401 M | - | - | 362 M | - | 1.15 B | - | 436 M | - | 1.1 B | - | 350 M | - | 956 M | 598 M | 274 M | - | 892 M | 604 M | 356 M | - | 1.26 B | 848 M | 423 M | - | 1.16 B | 782 M | 387 M | - | 1.15 B | 759 M | 386 M | - | 1.08 B | 726 M | 358 M | - | 1.04 B | 697 M | 349 M | - | 1.09 B | 745 M | 382 M | - | 1.12 B | 748 M | 386 M | - | 1.05 B | 696 M | 341 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.26 B | 274 M | 700 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Happiness Biotech Group Limited
HAPP
|
380 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | China |
 |
AstraZeneca PLC
AZN
|
5.73 B | - | - | $ 96.9 B |  Britain |
 |
Athira Pharma
ATHA
|
972 K | - | - | $ 269 M | USA |
 |
Compugen Ltd.
CGEN
|
475 K | $ 2.66 | 0.38 % | $ 249 M |  Israel |
 |
Galera Therapeutics
GRTX
|
20 K | - | -32.59 % | $ 7.61 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | USA |
 |
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
4.93 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
5 K | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
1.74 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
58.8 M | - | - | $ 3.37 B | China |
 |
Coherus BioSciences
CHRS
|
1.3 M | $ 1.73 | 5.49 % | $ 203 M | USA |
 |
Anika Therapeutics
ANIK
|
5.37 M | $ 14.8 | -0.6 % | $ 212 M | USA |
 |
Celldex Therapeutics
CLDX
|
3.38 M | $ 31.91 | 3.44 % | $ 2.12 B | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 3.33 | -3.2 % | $ 5.48 M | Israel |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
7.72 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
700 K | $ 22.01 | 4.26 % | $ 2.8 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | USA |